logo
Florida Seeks Drug Prescription Data With Names of Patients and Doctors

Florida Seeks Drug Prescription Data With Names of Patients and Doctors

New York Times05-03-2025
Florida's insurance regulator has demanded an unusually intrusive trove of data on millions of prescription drugs filled in the state last year, including the names of patients taking the medications, their dates of birth and doctors they've seen.
The Florida Office of Insurance Regulation in January sought this information from pharmacy benefit managers like UnitedHealth's Optum Rx and CVS Health's Caremark, companies that oversee prescription drugs for employers and government programs.
It remained unclear why the state was ordering the submission of so much data. In a letter to one benefit manager reviewed by The New York Times, the regulator said the state required the data to review whether the benefit managers, known as P.B.M.s, were compliant with a 2023 state law aimed at lowering drug prices and reining in the managers.
But the demand is sparking concerns about government overreach and patient privacy.
'You don't need such granular patient information for purposes of oversight,' said Sharona Hoffman, a health law and privacy expert at Case Western Reserve University. She added: 'You have to worry: Is the government actually trying to get information about reproductive care or transgender care or mental health care?'
Florida's six-week abortion ban, enacted by Gov. Ron DeSantis, a Republican, and the state's Republican-dominated legislature, requires that doctors who prescribe abortion pills dispense them in person, not through the mail. Another Florida law banned transgender transition care for minors and made it harder for adults to seek such care. Last year, a judge struck down key parts of that law, though it is still being enforced while the legal fight makes its way through the courts.
The data requested by the state could, in theory, be used to determine whether physicians are complying with those laws.
It was also unclear whether any of the benefit managers had complied and turned over the information to the state.
Some benefit managers and the employers that hire them to handle prescription drug benefits for their workers have also criticized the state's demand.
A group of large employers, the American Benefits Council, is asking the Florida regulator to withdraw its order to turn over the information. In a letter to the state, the council's lawyers wrote that the 'demand impermissibly violates the health privacy and security of millions of Floridians,' and that the state had not clearly outlined its authority or reasons for the action.
'We have a duty to employees and their data,' Katy Johnson, the president of the council, said in an interview.
Shiloh Elliott, a spokeswoman for Florida's insurance regulator, said that objections to the state's data request 'are clearly from those who do not want to be regulated or have any oversight in their industry.' She said the office 'will continue to request data in the best interest to protect consumers.'
Rosa Novo, the administrative benefits director for Miami-Dade County Public Schools, which provides health coverage to about 45,000 people, said in an interview that while she appreciated the state's efforts to address drug prices, it was unclear why it would need this level of detailed information about patients and their medications.
'My doctor is the only one who should know that,' Ms. Novo said.
Federal privacy law allows benefit managers to hand over limited data about individual patients in certain circumstances, such as when regulators are conducting an audit. But, according to experts, Florida's data request could violate the law because it is so broad and may go beyond what the regulator needs to conduct its review.
Experts said that another concern with Florida's request is that when sensitive patient data is in multiple hands, it raises the risk of a breach in which the information may be stolen.
Ms. Elliott, the spokeswoman for the regulator, said those concerns 'should be addressed to the actual health care insurance companies that have had countless data breaches exposing millions of Americans' sensitive information.'
Florida's data order was first reported by Bloomberg.
Like other states, Florida already has access to some of the data it is seeking, such as detailed information about prescriptions that are paid through Medicaid. But that data is generally strictly walled off, accessible only to staff members whose jobs require it.
Benefit managers often field requests from government regulators asking for slices of data to conduct audits or investigations. Such requests typically ask benefit managers to strip out patient names, and other identifying details, or ask for a small sample of patient claims.
By comparison, Florida's data request was 'pretty expansive and unprecedented,' said Joseph Shields, the president of a group of smaller benefit managers, Transparency-Rx.
Florida sought data not only on Florida residents, but also on patients who may have filled a prescription while visiting the state. Its request included patients covered through the federal Medicare program and commercial plans through employers that are regulated under federal law rather than state law, according to the regulator's letter to one benefit manager reviewed by The Times.
The Prescription Drug Reform Act, the Florida law the regulator used to justify the data request, imposed new reporting requirements on the benefit managers but said nothing about a mandate requiring them to turn over such detailed patient information. Benefit managers have fiercely fought efforts to scrutinize their business practices.
Florida's data request was first reported by Bloomberg.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

No, California is not guaranteed to remain an abortion haven
No, California is not guaranteed to remain an abortion haven

San Francisco Chronicle​

timea day ago

  • San Francisco Chronicle​

No, California is not guaranteed to remain an abortion haven

The sudden closure of five Planned Parenthood clinics in Northern California last week reveals a sad, stark truth: California is not the national 'haven' for abortion rights that it has aspired to be since the Supreme Court overturned Roe v. Wade in 2022. No state could be under Republican rule in Washington, or while federal law trumps state law, the Supreme Court majority opposes abortion rights and clinics are reliant on federal money to survive. There are few options to fix this problem, even in California, the world's fourth-largest economy. The state barely covered its budget deficit this year, and it has holes to fill as federal funds for public universities, education, transportation and other sectors were slashed in the recently passed budget. Plus, the state needs federal dollars to help rebuild Los Angeles after the devastating wildfires there earlier this year. Ten million Americans are expected to lose their health insurance because of nearly $1 trillion in Medicaid cuts over the next decade in the One Big Beautiful Bill Act, according to the nonpartisan Congressional Budget Office. Meanwhile, the wealthiest Americans will receive a disproportionate share of the tax cuts funded by those reductions, according to the Center for Budget and Policy Priorities. 'It's an illustration of the limits on what any state can do (on abortion access) if the federal government is hostile,' said Mary Ziegler, a professor of law at UC Davis and leading scholar on abortion rights. 'It's more of a reminder that there isn't really a real sanctuary. California has limited power over a lot of this.' It is the latest example of how California is in the political crosshairs of what President Donald Trump's former top adviser Steve Bannon famously described as his 'muzzle velocity' philosophy of launching a lot of disruptive policies and spurious attacks simultaneously. California is withering under the incoming fire. The people hurt most by the closure of those clinics will be the poorest Californians, as 80% of the people who used services at those clinics were Medicaid recipients, according to Planned Parenthood Mar Monte, the umbrella organization for the shuttered clinics. Planned Parenthood doesn't just provide abortion services. The majority of people go to Planned Parenthood clinics for contraceptive services, sexually transmitted infection testing, pregnancy testing and gynecological services. One in 10 (11%) female Medicaid beneficiaries ages 15 to 49 who received family planning services went to a Planned Parenthood clinic in 2021, according to the nonpartisan Kaiser Family Foundation. California has the highest percentage (29%) of Medicaid recipients in the country who go there for health care. This wasn't the way it was supposed to go. California was supposed to be a haven for abortion rights after the Supreme Court overturned Roe v. Wade. Shortly after the decision, Gov. Gavin Newsom joined the governors of Washington and Oregon to create what he called 'the West Coast offensive. A road map for other states to stand up for women.' A diverse coalition of abortion rights advocates formed the California Future of Abortion Council. It proposed more than 50 recommendations for policymakers to improve abortion access in the state. In the year after the decision, Newsom and the Democratic-controlled Legislature created more than a dozen new laws and invested more than $200 million to increase access across the state. In November 2022, 67% of California voters supported a ballot measure enshrining abortion rights in the state Constitution. Newsom spent $100,000 from his campaign coffers to plant billboards in seven states with some of the nation's most restrictive laws: 'Need an abortion?' reads one billboard. 'California is here to help.' 'What you do in California sets the standard for everyone else,' Mini Timmaraju, national president of NARAL Pro-Choice America, said at a 2022 fundraiser for Proposition 1 in San Francisco that Hillary Clinton attended. 'I want to take that package of legislation and this proposition and see it copied nationwide.' Ultimately, all those California laws and all that state funding weren't enough to keep the Mar Monte clinics open. They never could be as long as there isn't the national right to an abortion that Roe provided and as long as women's health clinics are reliant on federal funds to remain open. Planned Parenthood estimates that 200 clinics nationwide could close. To meet this reality, California needs a new 'West Coast offensive.' It needs to draw up a new 'road map for other states to stand up for women.' It would be best if clinics were funded privately, insulating them from partisan federal cuts. But that is harder now. California is the state with the most millionaires and billionaires. Now is the time for wealthy individuals and foundations to stand up and backfill these losses so clinics can continue to provide access to women's health care. But will those individuals step forward? Or will they be cowed like the wealthy law firms and Ivy League universities that have bowed to Trump's intimidation? Even if they do step up, is there enough private money in California to keep federally funded women's health clinics open until Democrats regain control of at least one lever of power in Washington and can curb his fascistic policies? That possibility looks bleak. For starters, it would probably require hundreds of millions of dollars, said Shannon Olivieri Hovis, former NARAL Pro-Choice California director who is now vice president of public affairs at Essential Access Health. 'I think the honest answer is, we don't know yet. We're talking about a huge hole.' Theresa Cheng, a professor of emergency medicine at UCSF and a member of the school's Bixby Center for Global Reproductive Health, said it will be difficult for the private sector to patch up all the new holes punctured in the social safety net by the Trump administration. 'That's going to be really difficult because the Trump administration has cut so broadly in so many social systems,' said Cheng, who is in touch with private donors through her work with several nonprofit organizations. 'Food insecurity. Homelessness. Immigration. There are a lot of needs out there now.' Relying on private donations isn't going to help clinics across California's chasm of wealth inequality, Ziegler said. 'If you're depending partly on individual donors, that's going to look very different in Beverly Hills or Marin County than it is in Gilroy or other areas where there are few people to give private donations,' Ziegler said. Until political change happens in Washington, Cheng urged Californians to 'stay stalwart in protecting reproductive health. So much of this will have to be settled out in the courts. That will at least buy us some more time.'

UnitedHealth (UNH) Is About to Report Q2 Earnings on July 29. Here Is What to Expect
UnitedHealth (UNH) Is About to Report Q2 Earnings on July 29. Here Is What to Expect

Business Insider

timea day ago

  • Business Insider

UnitedHealth (UNH) Is About to Report Q2 Earnings on July 29. Here Is What to Expect

UnitedHealth (UNH), one of the prominent players in the health insurance space, is scheduled to announce its second-quarter earnings on July 29. The stock has dropped 43.8% year-to-date, hit by several issues, including the suspension of its guidance, escalating medical costs, and a leadership shakeup that included the sudden departure of its CEO, Andrew Witty. Wall Street analysts expect the company to report earnings per share of $4.48, representing a 34% decrease year-over-year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Meanwhile, revenues are expected to increase by 13% from the year-ago quarter to $111.5 billion, according to data from the TipRanks Forecast page. It's important to note that UNH has an impressive track record with earnings, having exceeded EPS estimates in eight out of the past nine consecutive quarters. On July 24, UnitedHealth Group (UNH) revealed in an SEC filing that it is under formal investigation by the Department of Justice (DOJ) over its Medicare billing practices. The company said it is cooperating with both civil and criminal probes into whether it improperly raised patient diagnoses to secure higher payments from the government. J.P. Morgan analyst Lisa Gill remains optimistic ahead of UnitedHealth's earnings, viewing the DOJ probe as part of a broader industry trend. She maintained an Overweight rating on the stock, expecting a potential rebound despite near-term uncertainty. Analyst's Views Ahead of UNH's Q2 Earnings Heading into the Q2 print, Deutsche Bank analyst George Hill lowered his price target to $328 from $362 but reiterated a Buy rating. The analyst noted that investor sentiment 'has deteriorated significantly' due to a series of unfavorable news. The top-rated analyst lowered his estimates, citing ongoing concerns around Optum Health, the company's healthcare services unit. Also, Leerink Partners analyst Whit Mayo lowered the price target for UNH stock to $340 from $355 and reiterated a Buy rating. He remains 'cautiously optimistic' about the stock heading into Q2 earnings, given the challenging backdrop. Options Traders Anticipate a Large Move Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry; the Options tool does this for you. Indeed, it currently says that move in either direction. Is UNH a Good Buy Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, five Holds, and one Sell assigned in the last three months. At $348.12, the average UnitedHealth stock price target implies a 23.86% upside potential.

J.P. Morgan Weighs In on UnitedHealth Stock Amid DOJ Scrutiny
J.P. Morgan Weighs In on UnitedHealth Stock Amid DOJ Scrutiny

Business Insider

timea day ago

  • Business Insider

J.P. Morgan Weighs In on UnitedHealth Stock Amid DOJ Scrutiny

UnitedHealth (NYSE:UNH) stock slipped again on Thursday, a familiar pattern in what's shaping up to be a rough year. Shares have tumbled 44% year-to-date, weighed down by a string of negative developments, including disappointing Q1 results, a CEO change, the suspension of guidance, and rising costs tied to UHC's Medicare Advantage members. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Thursday's 5% drop was driven by renewed scrutiny over an ongoing legal matter. UNH disclosed that it had proactively reached out to the DOJ following a February Wall Street Journal report revealing a civil investigation into its Medicare Advantage risk-coding practices. In its latest filing, the company confirmed that it is now responding to formal civil and criminal inquiries, has launched its own internal review, and remains cooperative with CMS audits. UNH also pointed to a favorable March ruling from a Special Master in a separate, long-running DOJ civil case as a sign of how past challenges have played out. This shift from 'unaware' in February to 'proactively cooperating' now isn't surprising to J.P. Morgan analyst Lisa Gill, who views the company's engagement as part of a broader defense of its practices. 'While we are not lawyers,' Gill noted, 'we note that if the court were to view this case similarly to previous ones brought forth by DOJ regarding the False Claims Act (FCA), we believe that this would place the burden of proof on the DOJ to prove improper coding.' Though the investigation has added another layer of uncertainty, Gill contextualizes it within broader industry trends. The analyst points to risk-adjustment programs like RADV and regulatory updates like V28 as ongoing efforts to refine coding practices across the Medicare Advantage landscape. Viewed through that lens, the current probes may ultimately reflect how companies have adapted, rather than acted improperly. Still, Gill acknowledges the ambiguity facing investors. The company's filing offers limited detail, and any legal proceedings stemming from the DOJ's inquiries are likely to be drawn out. Much could hinge on the outcome of the ongoing DOJ-backed civil case – one in which the Special Master recently recommended dismissal due to lack of evidence, though the DOJ has challenged that recommendation. In the meantime, Gill is looking ahead to next week's earnings call for added clarity, and remains optimistic. The analyst assigns UNH an Overweight (i.e., Buy) rating and $418 price target, suggesting the stock could rebound by 48% over the next 12 months. (To watch Gill's track record, click here) And she's not alone. 17 other analysts share Gill's bullish outlook, while 5 remain on the sidelines and just one is bearish. Altogether, the stock carries a Moderate Buy consensus rating. The average price target stands at $348.12, implying a ~24% upside from current levels. (See UNH stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store